Recently, Fosun Pharma and its subsidiary Guilin Pharma Co., Ltd. have been listed "Top 100 International Pharmaceutical Enterprises in 2015" conducted by China Chamber of Commerce for Import & Export of Medicines & Health Products by virtue of the influence in the international market. Especially, Fosun Pharma won "Best Overseas Pharmaceutical Investment Enterprise in 2015", while Guilin Pharma Co., Ltd. was awarded "Excellent Suppliers and Partners in International Market in 2015" and came top in "Preparations International Leading Enterprises in2015”.

Fosun Pharma, one pharmaceutical enterprise who earlier started international development strategy, has initially international manufacturing capacity, with several production lines passing relevant international certification and part of preparations and bulk drug products entering international market on a scale. In the global market, Fosun Pharma has become the pioneer in development and manufacture of anti-malaria drugs. InChina, all antimalarial medicines of Guilin Pharma are self-owned brand finished medicines, representing approximately 70% to 80% of the total output of Chinese antimalarial finished products, and they are also the major medicines that Chinese government benefitsAfrica.

Guilin Pharma is Chinese largest manufacturer of the artemisinin-based drug to pass WHO Prequalification, becoming the only pharmaceutical company inChinapassing this qualification. The self-developed artesunate series medicines are currently one of the most effective antimalarial drugs in international market. As for antimalarial drugs in international market where some multinational corporations such as Novartis Pharmaceuticals and many India companies is competing fiercely, Guilin Pharma represents the top level of malaria treatments R&D and production in China.

In the past ten years, Guilin Pharma has had 13 antimalarial drug preparations passing WHO Prequalification, including 3 injections and 10 oral preparations covering malaria prevention, non-severe malaria treatment and severe malaria rescue. Guilin Pharma is the only pharmaceutical company in Chinapassing WHO Qualification, especially Artesun (Artesunate for injection), an innovative medicine preferred for being against severe malaria recommended by WHO.

Fosun Pharma, a pharmaceutical group with a certain scale in China and who is the first to keep pace of internationalization, will benefit from the current pharmaceutical market and industry policy environment, continuing to strengthen industry operation and put more resources into supporting product innovation and market expansion as well as actively carrying out mergers and acquisitions, the rapid expansion of industry scale and enhancement of the overall market competitiveness centering on the concerns of treatment field.